- Home
- APVO vs TOVX Comparison
APVO vs TOVX Comparison
Compare APVO & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- TOVX
- Stock Information
- Founded
- APVO 2016
- TOVX 2001
- Country
- APVO United States
- TOVX United States
- Employees
- APVO N/A
- TOVX N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- TOVX Health Care
- Exchange
- APVO Nasdaq
- TOVX Nasdaq
- Market Cap
- APVO 5.4M
- TOVX 4.7M
- IPO Year
- APVO N/A
- TOVX 2006
- Fundamental
- Price
- APVO $3.47
- TOVX $1.55
- Analyst Decision
- APVO Strong Buy
- TOVX Strong Buy
- Analyst Count
- APVO 1
- TOVX 1
- Target Price
- APVO $296.00
- TOVX $6.00
- AVG Volume (30 Days)
- APVO 44.0K
- TOVX 136.3K
- Earning Date
- APVO 03-04-2025
- TOVX 03-24-2025
- Dividend Yield
- APVO N/A
- TOVX N/A
- EPS Growth
- APVO N/A
- TOVX N/A
- EPS
- APVO N/A
- TOVX N/A
- Revenue
- APVO N/A
- TOVX N/A
- Revenue This Year
- APVO N/A
- TOVX N/A
- Revenue Next Year
- APVO N/A
- TOVX N/A
- P/E Ratio
- APVO N/A
- TOVX N/A
- Revenue Growth
- APVO N/A
- TOVX N/A
- 52 Week Low
- APVO $3.01
- TOVX $1.14
- 52 Week High
- APVO $399.60
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- APVO 33.42
- TOVX 52.70
- Support Level
- APVO $3.20
- TOVX $1.54
- Resistance Level
- APVO $3.65
- TOVX $1.75
- Average True Range (ATR)
- APVO 0.34
- TOVX 0.13
- MACD
- APVO 0.01
- TOVX 0.02
- Stochastic Oscillator
- APVO 31.51
- TOVX 66.67
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.